Answers are grounded in this paper and cite their sources.
We read the paper by Goh et al. with interest.1 After 30 years of experience in Helicobacter pylori treatment the ideal regimen to treat this infection has yet to be found.2 Nowadays, apart from having to know first-line eradication regimens well, we must also be prepared to face treatment failures.3, 4 In their recent study Goh et al. showed that, in patients in whom a standard proton pump inhibitor (PPI)-based triple therapy has previously failed, a second-line 2-week high dose PPI-amoxicillin dual therapy followed by a third-line PPI-amoxicillin-levofloxacin triple therapy was highly successful in achieving H. pylori eradication.1 Similarly, some years ago we obtained encouraging results with a third-line combination of PPI-amoxicillin-levofloxacin in a Spanish pilot study.5 We have just updated these results in 200 patients and confirmed the efficacy and tolerability of this regimen [10-day levofloxacin(500 mg b.d.), amoxicillin(1 g b.d.) and omeprazole(20 mg b.d.)], in patients with two consecutive eradication failures (standard triple therapy and bismuth-quadruple therapy). Per-protocol and intention-to-treat eradication rates were 73% and 68%. These figures (although not as high as the 90% cure rate obtained by Goh et al.1) seem encouraging, especially when it is taken into account that our rescue regimen was prescribed empirically after two eradication failures. Furthermore, this regimen was well-tolerated, with adverse effects reported in 19% of the patients, and most were mild to moderate in severity and transient: myalgia (8%), nausea (6%), metallic taste (5%), abdominal pain (3%), and diarrhoea (3%). Other authors have also reported encouraging experience with levofloxacin-containing treatments in patients in whom two consecutive eradication treatments have failed (Table 1), with cure rates ranging from 60% to 86%.5-10 Mean eradication rate calculated from these six studies was 73%. However, the sample size of the individual studies was low, with only 350 in total when all studies were considered. To the best of our knowledge, our experience with 200 patients is the largest to evaluate a levofloxacin-containing third-line regimen. 1st: PPI + C + A or M 2nd: PPI + C + A or M; Q 1st: PPI + C + A 2nd: Q 1st: PPI + C + A 2nd: Q 1st: PPI + C + A 2nd: Q In summary, a 10-day levofloxacin-containing triple therapy regimen is an encouraging third-line strategy and a safe and simple alternative after multiple previous H. pylori eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole and tetracycline. Declaration of personal and funding interests: None.
No takes yet. Share an insight, caveat, or question.
Javier P. Gisbert (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: